| Exendin - 4 is the first incretin mimetic that is permitted in the United States for the treatment of type 2 diabetes (T2DM), mainly used for metformin and sulfonylurea drug therapy in patients with T2DM not satisfactory. It is giving the hope for treatment of type 2 diabetes.Incretin mimetic has many good phys iological function: the enhancement of glucose-dependent insulin secretion ;suppression of inappropriately elevated glucagon secretion ; enhancement of insulin sensitivity ;slowing of gastric emptying and inhibition of appetite;promote neogenesis ofβ-cell; lowering triglycerides and so on.Incretin mimetic is a small molecular poly-peptide.It has many therapeutic mechanisms.The first is glucose-dependent insulin secretion.That is the blood glucose is hight, incretin mimetic can reduce the glucose.As the blood glucose descends,the action weakens.That can reduce the hypogyluce,it is safety. Incretin mimetic is slowing of gastric emptying and inhibition of appetite,and abating resist insulin.That can slower the develop of T2DM.The applization of incretin mimetic is extensive,it can reduce the blood glucose, especially postprandial blood glucose.The primary deathful cause of T2DM is the cardiovascular complications.Exendin - 4 reduces the cardiovascular complications through reducing FPG,PBG,HbA1C and postprandial blood glucose drift caused by fluctuations. It can reduce the occurrence of cardiovascular events through losing weight,lowering triglycerides and diastolic blood pressure..So these characters make Exendin– 4 have a wide range of clinical applications.
|
PDF Full Text Request